PubRank

Thomas J Polascik

Author PubWeight™ 128.96‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. Eur Urol 2008 4.75
2 Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol 2007 2.42
3 The state of prostate MRI in 2013. Oncology (Williston Park) 2013 2.33
4 Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology 2009 2.09
5 Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. J Urol 2010 2.05
6 Use of 111in-capromab pendetide immunoscintigraphy to image localized prostate cancer foci within the prostate gland. J Urol 2009 2.03
7 Promoter hypermethylation profile of kidney cancer. Clin Cancer Res 2004 2.02
8 Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiol Biomarkers Prev 2008 1.99
9 Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur Urol 2012 1.95
10 Bilateral focal ablation of prostate tissue using low-energy direct current (LEDC): a preclinical canine study. BJU Int 2013 1.89
11 Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol 2009 1.85
12 Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. BJU Int 2007 1.71
13 Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer 2008 1.71
14 Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. Cancer 2010 1.59
15 Factors predicting prostatic biopsy Gleason sum under grading. J Urol 2009 1.59
16 Complications of laparoscopic and percutaneous renal cryoablation in a single tertiary referral center. Eur Urol 2010 1.53
17 Overcoming challenges in designing and implementing a phase II randomized controlled trial using a presurgical model to test a dietary intervention in prostate cancer. Clin Trials 2008 1.48
18 Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002 1.48
19 Current status of minimally invasive ablative techniques in the treatment of small renal tumours. Eur Urol 2006 1.47
20 Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. J Urol 2010 1.45
21 Predicting occult multifocality of renal cell carcinoma. Eur Urol 2010 1.45
22 Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int 2011 1.37
23 Treatment of localised renal cell carcinoma. Eur Urol 2011 1.29
24 Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer 2007 1.27
25 Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology 2009 1.18
26 Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. Urology 2008 1.15
27 Complications after percutaneous radiofrequency ablation of renal tumors. Urology 2005 1.10
28 Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. BJU Int 2008 1.07
29 Can the conventional sextant prostate biopsy accurately predict unilateral prostate cancer in low-risk, localized, prostate cancer? Urol Oncol 2009 1.07
30 Acoustic radiation force impulse imaging of human prostates: initial in vivo demonstration. Ultrasound Med Biol 2011 1.06
31 Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int 2009 1.06
32 Acoustic radiation force impulse imaging of human prostates ex vivo. Ultrasound Med Biol 2010 1.04
33 Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer 2011 1.04
34 Characterizing stiffness of human prostates using acoustic radiation force. Ultrason Imaging 2010 1.04
35 Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. BJU Int 2010 1.04
36 Update on cryotherapy for prostate cancer in 2006. Curr Opin Urol 2006 1.03
37 Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy. BJU Int 2008 1.03
38 Predicting unilateral prostate cancer on routine diagnostic biopsy: sextant vs extended. BJU Int 2009 1.01
39 Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. Cancer 2010 0.98
40 Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology 2007 0.98
41 Cigarette smoking is associated with advanced renal cell carcinoma. J Clin Oncol 2011 0.98
42 Prostate cancer: the new landscape. Curr Opin Urol 2009 0.97
43 Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? Urology 2009 0.97
44 Focal therapy for prostate cancer: possibilities and limitations. Eur Urol 2010 0.97
45 Understanding the pathological features of focality, grade and tumour volume of early-stage prostate cancer as a foundation for parenchyma-sparing prostate cancer therapies: active surveillance and focal targeted therapy. BJU Int 2011 0.96
46 Factors predicting early and late phase decline of sexual health-related quality of life following radical prostatectomy. J Sex Med 2011 0.96
47 Supplement use among men with prostate cancer. Urology 2005 0.95
48 Effect of freeze time during renal cryoablation: a swine model. J Endourol 2006 0.95
49 Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. Urology 2004 0.94
50 Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. J Urol 2011 0.94
51 Role of multiparametric magnetic resonance imaging (MRI) in focal therapy for prostate cancer: a Delphi consensus project. BJU Int 2014 0.93
52 Effect of low-fat diets on plasma levels of NF-κB-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. Cancer Prev Res (Phila) 2011 0.92
53 Clinical predictors of renal mass pathological features. BJU Int 2010 0.92
54 A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy. J Clin Anesth 2009 0.91
55 Management of small renal tumors with radiofrequency ablation. Urology 2003 0.91
56 The effect of noise-cancelling headphones or music on pain perception and anxiety in men undergoing transrectal prostate biopsy. Urology 2012 0.91
57 Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. BJU Int 2010 0.90
58 Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer 2002 0.90
59 Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence? Urology 2009 0.90
60 Autoimmune testicular vasculitis. Urology 2003 0.88
61 The rise of ablative technologies for treating the small renal mass. Eur Urol 2007 0.88
62 Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era. Anticancer Res 2014 0.88
63 Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans. BJU Int 2010 0.87
64 Focal cryotherapy for prostate cancer. Curr Urol Rep 2010 0.87
65 Role of oxidative stress in a rat model of radiation-induced erectile dysfunction. J Sex Med 2012 0.87
66 Radiation-induced erectile dysfunction using prostate-confined modern radiotherapy in a rat model. J Sex Med 2011 0.87
67 Analysis of laterality and percentage of tumor involvement in 1386 prostatectomized specimens for selection of unilateral focal cryotherapy. Technol Cancer Res Treat 2007 0.87
68 Small renal mass biopsy--how, what and when: report from an international consensus panel. BJU Int 2014 0.86
69 Renal cryoablation and radio frequency ablation: an evaluation of worst case scenarios in a porcine model. J Urol 2005 0.86
70 Hypertonic saline-augmented radiofrequency ablation of the VX-2 tumor implanted in the rabbit kidney: a short-term survival pilot study. Urology 2002 0.86
71 Transdermal nicotine for analgesia after radical retropubic prostatectomy. Anesth Analg 2008 0.85
72 Flaxseed-derived enterolactone is inversely associated with tumor cell proliferation in men with localized prostate cancer. J Med Food 2013 0.85
73 Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer. Med Oncol 2012 0.85
74 Prostatic alpha-linolenic acid (ALA) is positively associated with aggressive prostate cancer: a relationship which may depend on genetic variation in ALA metabolism. PLoS One 2012 0.84
75 Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy. Anesth Analg 2009 0.84
76 Prostate biopsy in selecting candidates for hemiablative focal therapy. J Endourol 2010 0.84
77 The role of early adopter bias for new technologies in robot assisted laparoscopic prostatectomy. J Urol 2007 0.84
78 Characteristics and outcomes of tumors arising from the distal nephron. Urology 2012 0.84
79 Tumor size and endophytic growth pattern affect recurrence rates after laparoscopic renal cryoablation. Urology 2009 0.84
80 Pathologic basis of focal therapy for early-stage prostate cancer. Nat Rev Urol 2009 0.83
81 The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. Int J Radiat Oncol Biol Phys 2012 0.83
82 Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria. Curr Urol Rep 2012 0.83
83 Clinical, pathologic, and functional outcomes after nephron-sparing surgery in patients with a solitary kidney: a multicenter experience. J Endourol 2012 0.82
84 Percutaneous cryoablation of renal lesions with radiographic ice ball involvement of the renal sinus: analysis of hemorrhagic and collecting system complications. AJR Am J Roentgenol 2011 0.81
85 Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Urology 2007 0.81
86 Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. Urol Oncol 2010 0.81
87 Contemporary results of focal therapy for prostate cancer using cryoablation. J Endourol 2010 0.81
88 Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer? Int J Urol 2014 0.81
89 Altered male physiologic function after surgery for prostate cancer: couple perspective. Int Braz J Urol 2009 0.81
90 Persistent contrast enhancement several months after laparoscopic cryoablation of the small renal mass may not indicate recurrent tumor. J Endourol 2008 0.81
91 Contrast enhancement on computed tomography after renal cryoablation: an evidence of treatment failure? J Endourol 2012 0.80
92 Prostate cancer: an evolving paradigm. J Endourol 2010 0.80
93 Short-term functional outcomes and complications associated with transperineal template prostate mapping biopsy. Urology 2013 0.80
94 Role of vitamin D(3) as a sensitizer to cryoablation in a murine prostate cancer model: preliminary in vivo study. Urology 2010 0.79
95 Comparative financial analysis of minimally invasive surgery to open surgery for small renal tumours < or =3.5 cm: a single institutional experience. Eur Urol 2006 0.79
96 Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis. BJU Int 2011 0.79
97 Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis. Abdom Imaging 2015 0.79
98 Analysis of urinary function using validated instruments and uroflowmetry after primary and salvage prostate cryoablation. Urology 2009 0.79
99 ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology. AJR Am J Roentgenol 2005 0.78
100 Current trends and new frontiers in focal therapy for localized prostate cancer. Curr Urol Rep 2015 0.78
101 Predicting biopsy-proven prostate cancer recurrence following cryosurgery. Urol Oncol 2010 0.78
102 Malignant cystic nephroma. Can J Urol 2006 0.78
103 Multiple nephron-sparing procedures in solitary kidney with recurrent, metachronous, nonfamilial renal cell carcinoma. Urology 2006 0.78
104 Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era? Curr Opin Urol 2015 0.77
105 Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007 0.77
106 Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2013 0.77
107 111-In-capromab pendetide imaging using hybrid-γ camera-computer tomography technology is not reliable in detecting seminal vesicle invasion in patients with prostate cancer. Urol Oncol 2010 0.77
108 Predicting participation in and successful outcome of a penile rehabilitation programme using a phosphodiesterase type 5 inhibitor with a vacuum erection device after radical prostatectomy. BJU Int 2012 0.77
109 Minimally invasive surgery using ablative modalities for the localized renal mass. Int J Urol 2009 0.77
110 Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men. BJU Int 2010 0.77
111 Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database. J Sex Med 2011 0.76
112 Ureteropelvic junction obliteration resulting in nephrectomy after radiofrequency ablation of small renal cell carcinoma. Urology 2007 0.76
113 Evolution of the concept of focal therapy for prostate cancer. Oncology (Williston Park) 2013 0.76
114 Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men. Urology 2009 0.76
115 Utilization of (111)In-Capromab pendetide SPECT-CT for detecting seminal vesicle invasion with recurrent prostate cancer after primary in situ therapy. Int J Urol 2009 0.76
116 The effect of cryoablation on the histologic interpretation of intraoperative biopsy of small clear cell renal carcinoma and renal oncocytoma. J Endourol 2008 0.76
117 How to select the right patients for focal therapy of prostate cancer? Curr Opin Urol 2014 0.76
118 Morphology of hypoxia following cryoablation in a prostate cancer murine model: its relationship to necrosis, apoptosis and, microvessel density. Cryobiology 2010 0.76
119 Renal function outcomes after laparoscopic renal cryoablation. J Endourol 2011 0.76
120 High-intensity focused ultrasound for focal therapy: reality or pitfall? Curr Opin Urol 2017 0.76
121 Recent advances in focal therapy of prostate and kidney cancer. F1000 Med Rep 2010 0.75
122 The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. BJU Int 2011 0.75
123 Editorial comment. Urology 2011 0.75
124 Prostate cancer treatment unblinded. Lancet Oncol 2012 0.75
125 Prostate cancer: ideal candidates for focal therapy. Nat Rev Urol 2011 0.75
126 Editorial comment. Urology 2010 0.75
127 Prostatic abscess as a delayed complication following cryosurgery for primary prostate cancer. Can J Urol 2007 0.75
128 Use of bipolar laparoscopic forceps to occlude and transect the retroperitoneal vasculature: a porcine model. J Endourol 2003 0.75
129 Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years? Urology 2008 0.75
130 New Frontiers in Imaging and Focal Therapy: Highlights From the Third International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer, February 24-27, 2010, Washington, DC. Rev Urol 2011 0.75
131 Ovarian hyperstimulation causing ureteral obstruction in a pregnant woman. Urology 2006 0.75
132 Low central venous pressure versus acute normovolemic hemodilution versus conventional fluid management for reducing blood loss in radical retropubic prostatectomy: a randomized controlled trial. Curr Med Res Opin 2014 0.75
133 Low-risk and very-low-risk prostate cancer: is there a role for focal therapy in the era of active surveillance? Yes, the two approaches complement each other. Oncology (Williston Park) 2014 0.75
134 Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy? Urology 2005 0.75
135 Preoperative predictors of pathologic stage T2a in low-risk prostate cancer: implications for focal therapy. Urol Int 2012 0.75
136 Metastatic ampullary adenocarcinoma presenting as a hydrocele: a case report. JOP 2014 0.75
137 Rectourethral fistula after combination radiotherapy for prostate cancer. Urology 2007 0.75
138 Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml. Urol Oncol 2012 0.75
139 Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection. Technol Cancer Res Treat 2009 0.75
140 Urothelial sloughing with obstruction after laparoscopic cryoablation of small renal carcinoma in solitary kidney. Urology 2008 0.75
141 Complications and postoperative events after cryosurgery for prostate cancer. BJU Int 2011 0.75
142 Impact of a cryotherapy training workshop on the adoption and utilization of cryotherapy in the community setting. Can J Urol 2008 0.75
143 Renal tumors in solid organ recipients: clinical and pathologic features. Urol Oncol 2011 0.75
144 Radiation exposure associated with dedicated renal mass computed tomography protocol: impact of patient characteristics. J Endourol 2013 0.75
145 Characteristics of patients diagnosed with both melanoma and renal cell cancer. Cancer Causes Control 2013 0.75
146 Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance. Med Oncol 2012 0.75